GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration agreement to enable the development of T-MAXIMUM’s development CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents.

GenScript will provide T-MAXIMUM Biotech with various CRISPR reagents to support the development of its universal CAR-T products from discovery to commercialization. The partnership with GenScript will support T-MAXIMUM Biotech’s strategic development plan to progress multiple products to the Phase II clinical research stage and deliver products to market within the next five years.

Dr. Shang Xiaoyun, CEO of T-MAXIMUM, said: “We are delighted to establish a strategic cooperation with GenScript. T-MAXIMUM focuses on recurrent high-grade gliomas without effective standard therapies and is committed to the development of universal CAR-T cell therapies. Gene editing reagents are crucial raw materials for the quality and efficacy of our products. We are confident that this collaboration will accelerate the regulatory processes in China and the United States, expediting T-MAXIMUM’s first product pipeline to benefit patients in need as soon as possible.”

“We are honored to collaborate with T-MAXIMUM Biotech,” said Dr. Li Hong, VP of R&D and manufacturing at GenScript. “Our R&D-to-GMP-level sgRNA will support their UCAR-T products for solid tumors. While CAR-T cell therapies have made remarkable strides in hematological tumors, addressing the unmet need for solid tumors remains crucial. We look forward to the further achievements of T-MAXIMUM Biotech’s cell therapy products—and to bringing good news to more patients.”